09:46 AM EST - Valeant Pharmaceuticals International, Inc. : today commented on the announcement that Allergan, Inc. and Actavis plc have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock. "We have seen the announcement that Allergan and Actavis have made, and while we will review any such agreement in determining our course of action, Valeant cannot justify to its own shareholders paying a price of $219 or more per share for Allergan," said J. Michael Pearson, Valeant Chairman and CEO. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading down $1.11 at $150.36.
